Clinical trials: Liver Cell Carcinoma Non-resectable
Hepatocellular Carcinoma Non-resectable
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable…
- Trial name
- ExTRACT-HCC (NCT04965454)
- Testing
- Fluorine-18 fluorocholine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Queen's Medical Center
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Hepatocellular Carcinoma
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin and raltitrexed plus lenvatinib and camrelizumab in patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT05003700
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Unresectable Hepatocellular Carcinoma (HCC)
Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)
- Trial name
- HLP1-1331 (NCT07596134)
- Testing
- Multimodal Thermal Therapy, Targeted and Immune Drugs
- Where
- 7 sites in China
- Volunteers
- 166 people
- Sponsor
- Zhejiang University
Liver Cancer
Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed
RATIONALE: The Chinese herbal medicine Sho-saiko-to contains ingredients that may slow the growth of tumor cells and stimulate a person's immune system to help kill tumor cells.
- Trial name
- NCT00040898
- Testing
- Sho-saiko-to
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Liver Cancer
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
Capecitabine is a chemotherapeutic that has been approved for use in breast and colorectal cancers. The advantages of capecitabine are that (1) it is an oral drug; and (2) it is less toxic than many other chemotherapeutics.
- Trial name
- NCT00076609
- Testing
- PHY906, capecitabine
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 31 people
- Sponsor
- PhytoCeutica
Hepatocellular Carcinoma
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma
- Trial name
- NCT05616390
- Testing
- Sintilimab, Bevacizumab, Liver Protective Support Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Unresectable Hepatocellular Carcinoma, Oligometastatic Disease
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
The goal of this phase 2 prospective clinical trial is to learn about the efficacy and safety of stereotactic body radiation therapy (SBRT) plus immunotherapy and targeted therapy in patients with unresectable or oligometastatic…
- Trial name
- NCT05917431
- Testing
- SBRT plus tislelizumab and regorafenib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking University Cancer Hospital & Institute
Carcinoma, Hepatocellular
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
Vast majority of patients with hepatocellular carcinoma (HCC) present with unresectable disease. In the last decade results of randomized trials and a subsequent metaanalyses established transarterial chemoembolization (TACE) or…
- Trial name
- TACE-SBRT (NCT02794337)
- Testing
- SBRT, TACE, Sorafenib
- Where
- 2 sites in India
- Volunteers
- 67 people
- Sponsor
- Tata Memorial Hospital
Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma
This study is evaluating the safety and potential effectiveness of adding folic acid to atezolizumab plus bevacizumab as first-line treatment for adults with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07835737
- Testing
- Folic Acid, Atezolizumab & Bevacizumab
- Volunteers
- 78 people
- Sponsor
- West China Hospital
Carcinoma, Hepatocellular, Hepatoma
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC).
- Trial name
- NCT00503867
- Testing
- SIR-Spheres microspheres
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sirtex Medical
Malignant Biliary Obstruction, Hepatocellular Carcinoma
Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC
The effectiveness and safety of fully covered metal stent in malignant biliary obstruction caused by HCC are still unknown. These would be clarified in this prospective cohort study.
- Trial name
- NCT05729867
- Testing
- Endoscpic biliary drainage using fully covered metal stent
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
The goal of this observational study is to evaluate how well first-line immunotherapy works and investigate its association with immune-related adverse events (irAEs) in Egyptian adults with unresectable hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable, Hepatocellular Carcinoma Metastatic
- Trial name
- NCT07904494
- Testing
- Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab
- Where
- 4 sites in Egypt
- Volunteers
- 294 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma
TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
TheraSphere is a medical device containing yttrium-90 (Y-90) a radioactive material that has been used to treat liver tumors. When Y-90 is put into very tiny glass beads (TheraSphere), it can be injected into the liver through a…
- Trial name
- NCT01349075
- Testing
- TheraSphere
- Where
- United States
- Volunteers
- 474 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hepatocellular Carcinoma
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
In India, majority of our patients have advanced hepatocellular carcinoma (HCC) at presentation and hence are unsuitable for the available curative treatment options. In such patients the treatment options are mainly palliative.
- Trial name
- NCT02240771
- Testing
- Transarterial chemotherapy, Oral chemotherapy
- Where
- India
- Volunteers
- 124 people
- Sponsor
- All India Institute of Medical Sciences
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
- Trial name
- NCT07110233
- Testing
- TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to…
- Trial name
- NCT02415036
- Testing
- Delcath Hepatic Delivery System, Melphalan
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- Delcath Systems Inc.
Breast Carcinoma, Carcinoma of Unknown Primary
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver…
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma
- Trial name
- NCT01366144
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Non-resectable
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who progressed after prior systemic therapy (targeted ± immunotherapy) are enrolled. Primary endpoint: objective response rate (ORR).
- Trial name
- NCT07192848
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Song Peng
Hepatocellular Carcinoma (HCC)
The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death globally. This retrospective, multicentric study will be coordinated by Dr.
- Trial name
- MANIFEST-HCC (NCT06903663)
- Where
- 4 sites in Romania
- Volunteers
- 100 people
- Sponsor
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor